Biohaven Pharmaceutical Holding Company Ltd. (BHVN) posted a quarterly loss of $ 2.63 per share compared to Zacks’ consensus estimate of a loss of $ 2.44. This compares to a loss of $ 3.27 per share a year ago. These figures are corrected for non-recurring items.
This quarterly report represents a surprise earnings of -7.79%. A quarter ago, this company was expected to record a loss of $ 2.77 per share when it actually produced a loss of $ 3.23, delivering a surprise of -16.61% .
Over the past four quarters, the company hasn’t been able to beat consensus EPS estimates.
Biohaven Pharmaceutical Holding Company Ltd., which is part of the Zacks Medical – Biomedical and Genetics industry, reported sales of $ 135.74 million for the quarter ended September 2021, exceeding 1.45% the Zacks consensus estimate. This compares to revenue of $ 17.66 million a year ago. The company has exceeded consensus revenue estimates four times in the past four quarters.
The sustainability of the immediate stock price movement based on recently released numbers and future earnings expectations will primarily depend on management feedback on the profit call.
The shares of Biohaven Pharmaceutical Holding Company Ltd. are up about 63.1% year-to-date compared to the S&P 500’s 25.2% gain.
What’s next for Biohaven Pharmaceutical Holding Company Ltd.
While Biohaven Pharmaceutical Holding Company Ltd. has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable metric that can help investors solve this problem is the company’s earnings outlook. This not only includes the current consensus earnings expectations for the coming quarter (s), but also how those expectations have changed in recent times.
Empirical research shows a strong correlation between short-term stock market movements and trends in earnings estimate revisions. Investors can follow these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Prior to this earnings release, the trend of revised estimates for Biohaven Pharmaceutical Holding Company Ltd. was mixed. While the magnitude and direction of estimate revisions may change as a result of the company’s just released earnings report, the current status results in a Zacks Rank # 3 (Hold) for the stock. Thus, stocks are expected to move in line with the market in the near future. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.
It will be interesting to see how the estimates for the next quarters and the current year evolve in the days to come. Current consensus estimate of EPS is – $ 2.17 on revenue of $ 156.37 million for the coming quarter and – $ 12.06 on revenue of $ 429.33 million for the year. In progress.
Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the stock. In terms of Zacks industry rankings, Medical – Biomedical and Genetics currently ranks in the bottom 40% of the 250+ Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.
Boom in infrastructure stocks will sweep America
A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.
The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “
Zacks published a special report to help you do just that, and today it’s free. Discover 7 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as freight transport and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>
Click to get this free report
Biohaven Pharmaceutical Holding Company Ltd. (BHVN): Free Stock Analysis Report
To read this article on Zacks.com, click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.